FY2024 Earnings Estimate for YS Biopharma Co., Ltd. Issued By Diamond Equity (NASDAQ:YS)

YS Biopharma Co., Ltd. (NASDAQ:YS) – Research analysts at Diamond Equity decreased their FY2024 EPS estimates for shares of YS Biopharma in a research note issued on Monday, April 22nd. Diamond Equity analyst H. Diamond now expects that the company will post earnings per share of ($0.45) for the year, down from their previous forecast of ($0.24). The consensus estimate for YS Biopharma’s current full-year earnings is ($0.24) per share. Diamond Equity also issued estimates for YS Biopharma’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.25) EPS.

YS Biopharma Price Performance

Shares of NASDAQ:YS opened at $0.80 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.09 and a current ratio of 1.41. The stock’s fifty day simple moving average is $0.66 and its two-hundred day simple moving average is $0.57. YS Biopharma has a 1-year low of $0.35 and a 1-year high of $1.97.

YS Biopharma (NASDAQ:YS) last issued its earnings results on Monday, January 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $13.64 million during the quarter.

Institutional Investors Weigh In On YS Biopharma

An institutional investor recently bought a new position in YS Biopharma stock. Superstring Capital Management LP bought a new stake in shares of YS Biopharma Co., Ltd. (NASDAQ:YS) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 307,920 shares of the company’s stock, valued at approximately $166,000. Superstring Capital Management LP owned approximately 0.33% of YS Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 52.64% of the company’s stock.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.